Beyond Cholesterol Lowering: Clinical Caution, Personalization, and Nutritional Integration in Statin Therapy
Nutrients · 24.02.2026 · 18 (5) · 722
DOI: 10.3390/nu18050722 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 24.02.2026. Verfasst von Giovanni Corsetti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Sciences, Università di Brescia, 25128 Brescia, Italy. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Cholesterol, LDL, Nutritional Status. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: private founder, Vittorio Bellani.
Abstract (Originalsprache)
Background
Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for atherosclerosis and cardiovascular disease (CVD). Statins are the cornerstone of LDL-C reduction and are highly effective in secondary prevention. However, their benefit in primary prevention among individuals at low-to-moderate cardiovascular risk remains controversial, and long-term adherence is often limited by adverse effects.
Methods
This narrative review summarizes current evidence on the clinical effectiveness of statin therapy, with particular attention paid to the role of nutritional status in modulating statin efficacy, safety, and interpretation of clinical outcomes.
Results
In primary prevention the effectiveness of statins in reducing cardiovascular events remains mixed. Furthermore, 20–30% of patients in secondary or high-risk prevention do not achieve clinically meaningful benefits despite adequate LDL-C lowering. More than half of statin-treated patients discontinue therapy within two years, most commonly because of adverse effects, without a corresponding increase in cardiovascular mortality. Emerging evidence suggests that malnutrition and sarcopenia may significantly influence statin pharmacokinetics and pharmacodynamics, thereby affecting both therapeutic response and susceptibility to adverse events. In addition, statin-induced lipid lowering may alter nutrition-related biomarkers, potentially leading to misclassification or overestimation of malnutrition.
Conclusions
Although statins remain effective agents for lowering LDL-C, their prescription should be embedded within an individualized, patient-centered approach. Current guidelines provide a robust methodological framework for statin use; however, their application should be contextualized rather than automatic. Optimal effectiveness is achieved when pharmacological therapy is integrated with dietary patterns, nutritional status, and lifestyle factors. Incorporating nutritional assessment into statin management may improve tolerability, enhance clinical outcomes, and enable more accurate cardiovascular risk stratification beyond standardized cholesterol-lowering strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Sciences, Università di Brescia, 25128 Brescia, Italy.
- Institute of Human Health, Ruaha Catholic University, Iringa P.O. Box 774, Tanzania.
ORCID-Profile: Giovanni Corsetti
Förderung
- private founder
- Vittorio Bellani
Zitieren
APA
Corsetti, G., & Pasini, E. (2026). Beyond Cholesterol Lowering: Clinical Caution, Personalization, and Nutritional Integration in Statin Therapy. Nutrients, 18(5), 722. https://doi.org/10.3390/nu18050722
Vancouver
Corsetti G, Pasini E. Beyond Cholesterol Lowering: Clinical Caution, Personalization, and Nutritional Integration in Statin Therapy. Nutrients. 2026;18(5):722. doi:10.3390/nu18050722
BibTeX
@article{Corsetti2026,
author = {Corsetti, Giovanni and Pasini, Evasio},
title = {Beyond Cholesterol Lowering: Clinical Caution, Personalization, and Nutritional Integration in Statin Therapy},
journal = {Nutrients},
year = {2026},
volume = {18},
number = {5},
pages = {722},
doi = {10.3390/nu18050722}
}
EUVIMED